These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2053 related items for PubMed ID: 25886655

  • 1. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
    Pringsheim T, Hirsch L, Gardner D, Gorman DA.
    Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
    [Abstract] [Full Text] [Related]

  • 2. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers.
    Pringsheim T, Hirsch L, Gardner D, Gorman DA.
    Can J Psychiatry; 2015 Feb; 60(2):52-61. PubMed ID: 25886656
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM.
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [Abstract] [Full Text] [Related]

  • 5. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH, Merry SN, Hetrick SE, Stasiak K.
    Cochrane Database Syst Rev; 2012 Sep 12; (9):CD008559. PubMed ID: 22972123
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
    Masi G, Manfredi A, Nieri G, Muratori P, Pfanner C, Milone A.
    J Clin Psychopharmacol; 2017 Oct 12; 37(5):590-594. PubMed ID: 28806385
    [Abstract] [Full Text] [Related]

  • 8. Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder.
    Wehmeier PM, Schacht A, Dittmann RW, Helsberg K, Schneider-Fresenius C, Lehmann M, Bullinger M, Ravens-Sieberer U.
    Qual Life Res; 2011 Jun 12; 20(5):691-702. PubMed ID: 21136299
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.
    Hazell P, Zhang S, Wolańczyk T, Barton J, Johnson M, Zuddas A, Danckaerts M, Ladikos A, Benn D, Yoran-Hegesh R, Zeiner P, Michelson D.
    Eur Child Adolesc Psychiatry; 2006 Mar 12; 15(2):105-10. PubMed ID: 16523251
    [Abstract] [Full Text] [Related]

  • 11. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A, LYCY Study Group.
    Eur Neuropsychopharmacol; 2009 Nov 12; 19(11):822-34. PubMed ID: 19716683
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF.
    J Atten Disord; 2004 Oct 12; 8(2):45-52. PubMed ID: 15801334
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Hazell P, Becker K, Nikkanen EA, Trzepacz PT, Tanaka Y, Tabas L, D'Souza DN, Witcher J, Long A, Ponsler G, Dittmann RW.
    Atten Defic Hyperact Disord; 2009 Dec 12; 1(2):201-10. PubMed ID: 20234828
    [Abstract] [Full Text] [Related]

  • 15. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder.
    Sinzig J, Döpfner M, Lehmkuhl G, German Methylphenidate Study Group, Uebel H, Schmeck K, Poustka F, Gerber WD, Günter M, Knölker U, Gehrke M, Hässler F, Resch F, Brünger M, Ose C, Fischer R.
    J Child Adolesc Psychopharmacol; 2007 Aug 12; 17(4):421-32. PubMed ID: 17822338
    [Abstract] [Full Text] [Related]

  • 16. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
    Holzer B, Lopes V, Lehman R.
    J Child Adolesc Psychopharmacol; 2013 Aug 12; 23(6):415-8. PubMed ID: 23952189
    [Abstract] [Full Text] [Related]

  • 17. Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
    Blader JC, Pliszka SR, Kafantaris V, Foley CA, Crowell JA, Carlson GA, Sauder CL, Margulies DM, Sinha C, Sverd J, Matthews TL, Bailey BY, Daviss WB.
    J Am Acad Child Adolesc Psychiatry; 2013 Dec 12; 52(12):1281-93. PubMed ID: 24290461
    [Abstract] [Full Text] [Related]

  • 18. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy.
    Hirota T, Schwartz S, Correll CU.
    J Am Acad Child Adolesc Psychiatry; 2014 Feb 12; 53(2):153-73. PubMed ID: 24472251
    [Abstract] [Full Text] [Related]

  • 19. Psychopharmacological treatment of oppositional defiant disorder.
    Turgay A.
    CNS Drugs; 2009 Feb 12; 23(1):1-17. PubMed ID: 19062772
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 103.